Biological Background

The Neuropeptide Y Receptor Type 2 (NPY2R), also known as the Y2 receptor, is a class A GPCR expressed in the central and peripheral nervous systems, regulating appetite suppression, glucose metabolism, and energy expenditure. NPY2R mediates distinct G-protein–independent β-arrestin signaling pathways alongside Gαi/o coupling, enabling comprehensive pharmacological characterization. NPY2R agonist and antagonist programs represent promising therapeutic strategies for obesity and metabolic disorders.

This bioassay kit supports pharmaceutical companies developing NPY2R-targeted therapies for obesity, metabolic syndrome, and energy balance disorders. Applications include comprehensive pharmacology profiling, ligand bias assessment, potency testing, and neutralizing antibody screening using a universal G-protein–independent platform.

Eurofins DiscoverX's PathHunter® NPY2R kit provides ready-to-use CHO-K1 cells engineered for sensitive β-arrestin recruitment detection via EFC technology, complementing G-protein–coupled cAMP assays for complete NPY2R mechanistic profiling.

Product Highlights
  • Ready-to-use cryopreserved cells: CHO-K1 NPY2R cells in single-use format enabling rapid implementation from hit identification to commercial QC and stability testing
  • Complete kit components: Includes cells, EFC-based β-arrestin recruitment detection reagents, cell plating media, positive control agonist (peptide YY), and 96-well assay plates
  • G-protein–independent β-arrestin assay: PathHunter® EFC technology captures NPY2R signaling independent of Gαi/o coupling, enabling comprehensive ligand characterization and biased agonism discovery
  • Ligand bias profiling platform: Compare β-arrestin recruitment versus cAMP inhibition in parallel assays to identify NPY2R ligands with preferred signaling bias for enhanced therapeutic profiles
  • Universal GPCR profiling complement: Ideal to generate comprehensive pharmacological profiles and identify functionally selective NPY2R modulators

PathHunter NPY2R Bioassay Assay Principle

PathHunter NPY2R Assay Principle

β-Arrestin Recruitment and PathHunter® Technology A. Upon peptide YY, NPY, or other NPY2R agonist binding, the activated NPY2R is phosphorylated by GPCR kinases, leading to β-arrestin-2 recruitment. This ligand-induced β-arrestin-2 recruitment activates signaling cascades independently of G-protein signaling to provide a stoichiometric, non-amplified signal. β-arrestin-2 binding blocks G-protein-mediated signaling and results in NPY2R internalization (endocytosis) and signal desensitization. Subsequently, the NPY2R is recycled back to the plasma membrane or degraded in the lysosome. This stoichiometric (1 receptor: 1 ligand), non-amplified system requires full ligand occupancy to generate maximum signal, which provides superior sensitivity for detecting NPY2R antagonists and improved differentiation between partial and full agonists compared to amplified second messenger systems. By analyzing the NPY2R β-arrestin pathway, researchers can fine-tune compound characterization when screening antagonists, distinguish between full, super, and partial agonists, and assess ligand bias by comparing β-arrestin recruitment versus Gαi/o-mediated cAMP inhibition profiles—critical for identifying functionally selective NPY2R modulators with optimized therapeutic profiles in obesity and metabolic disorders.

B. PathHunter® NPY2R bioassays utilize Enzyme Fragment Complementation (EFC) technology. NPY2R is fused with the small enzyme donor fragment ProLink™ (PK) and co-expressed in CHO-K1 cells stably expressing β-arrestin-2 fused to the larger enzyme acceptor fragment (EA). NPY2R activation by peptide YY, NPY, or test compounds stimulates β-arrestin-2 recruitment to the PK-tagged receptor, forcing complementation of the enzyme fragments and reconstituting active β-galactosidase enzyme. This interaction produces measurable enzyme activity detected using chemiluminescent PathHunter Detection Reagents. The β-arrestin recruitment assay offers an easy-to-use complement to cAMP inhibition assays, enabling comprehensive NPY2R compound pharmacology characterization and ligand bias assessment—a universal platform that expands opportunities for developing novel NPY2R-targeted therapeutics with improved efficacy and safety profiles for obesity and metabolic disorders.